Unicorn Nest news
Amolyt Pharma Raises $80M in Series B Financing
- Amolyt Pharma from Lyon develops therapeutic peptides for rare endocrine and related diseases. - The company closed an $80m Series B round. - The round was co-led by Sectoral Asset Management and Andera Partners, with participation from ATEM Capital, LSP, Novo Holdings (Novo Ventures), Kurma Partners, Mass General Brigham Ventures, Innobio 2 managed by Bpifrance, Orbimed, Pontifax, Eurazeo, Sham Innovation Santé/Turenne Capital and Credit Agricole Creation. - The company plans to use the proceeds from the financing to advance its pipeline of potential therapeutics for rare endocrine and related diseases, including clinical development of AZP-3601 for hypoparathyroidism, pre-clinical development of AZP-3813 for acromegaly and ongoing research related to AZP-3404, and to further expand its early-stage pipeline through both internal research and development activities and potential in-licensing opportunities.
Unicorn Nest news
Amolyt Pharma Raises $80M in Series B Financing
- Amolyt Pharma from Lyon develops therapeutic peptides for rare endocrine and related diseases. - The company closed an $80m Series B round. - The round was co-led by Sectoral Asset Management and Andera Partners, with participation from ATEM Capital, LSP, Novo Holdings (Novo Ventures), Kurma Partners, Mass General Brigham Ventures, Innobio 2 managed by Bpifrance, Orbimed, Pontifax, Eurazeo, Sham Innovation Santé/Turenne Capital and Credit Agricole Creation. - The company plans to use the proceeds from the financing to advance its pipeline of potential therapeutics for rare endocrine and related diseases, including clinical development of AZP-3601 for hypoparathyroidism, pre-clinical development of AZP-3813 for acromegaly and ongoing research related to AZP-3404, and to further expand its early-stage pipeline through both internal research and development activities and potential in-licensing opportunities.
Unicorn Nest news
Cardior Raises €64M in Series B Funding
– Cardior Pharmaceuticals from Hanover develops non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases.
– The company closed a €64m ($76m) Series B financing round.
– The round was led by Inkef Capital, supported by fellow new investors Fund+, Sunstone, Hadean Ventures and Coparion with participation from existing investors including LSP, BioMedPartners, Bristol Myers Squibb and High-Tech Gründerfonds.
– The new investment will be used for the late-stage clinical development of its lead program and the expansion of its earlier-stage pipeline.
Unicorn Nest news
Visus Therapeutics Raises $20M in Funding
– Visus Therapeutics from Seattle develops innovative ophthalmic therapies to improve vision for people around the world.
– The company raised $20m in funding.
– The round was led by LSP in Amsterdam with participation from Sage Partners of Hong Kong, Johnson & Johnson Innovation -JJDC, Inc. and other inside investors.
– The new investment will be used to advance its clinical and commercial efforts for lead asset BRIMOCHOL under investigation for presbyopia as well as new research and development activities in its drug development pipeline.
Unicorn Nest news
T-knife Therapeutics Closes $110M Series B Financing
– T-knife Therapeutics, Inc. from Berlin, Germany develops T-cell receptor (TCR) therapeutics for solid tumor patients.
– Company completed a $110m Series B financing.
– The round was led by Fidelity Management & Research Company, LLC., with participation from other new investors including LSP, Qatar Investment Authority (QIA), Casdin Capital, Sixty Degree Capital, and CaaS Capital, along with existing investors RA Capital Management, Versant Ventures and founding investor Andera Partners.
– The new investment will be used to expand the company’s scientific team, increase manufacturing capacity and advance its pipeline of TCR-T.
Unicorn Nest news
Xilis Raises $70 Million Series A Financing to Advance Diagnostic and Drug Discovery and Development Platform Leveraging Proprietary MicroOrganoSphere™ Technology
– Xilis, Inc. announced the close of a $70m Series A financing.
– The round was led by Mubadala Capital and joined by new investors including GV, LSP, Catalio Capital Management, and Duke Angel Network.
– Current investors Felicis Ventures, Two Sigma Ventures, Pear VC, KdT Ventures, and Alix Ventures also participated.
– Xilis is based on decades of biomedical, oncology, and stem cell research by its three co-founders.
– Dr. Clevers, a Breakthrough Prize winner, is the inventor and pioneer of the organoid technology.
– Dr. Shen and Dr. Hsu are accomplished engineering and medical professors at Duke University and experts in precision medicine.